Drug intelligence / Profile preview

lactobacillus rhamnosus TT-628

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Lactobacillus rhamnosus* TT-628 is a specific probiotic strain investigated for its potential therapeutic effects in neurological disorders, specifically epilepsy. As part of a microbial therapy approach, it is studied as an adjunctive treatment to standard antiepileptic drugs to help manage uncontrolled seizures. The strain is believed to exert its effects through the gut-brain axis, potentially modulating neuroinflammation, neurotransmitter levels (such as GABA), and the intestinal microbiome composition. Clinical research, primarily led by West China Hospital of Sichuan University, evaluates its safety and efficacy when administered orally, often in combination with other probiotic strains like *Bacteroides fragilis* BF839.

Other names: Lactobacillus rhamnosus TT-628L. rhamnosus TT-628

Beyond the preview

Go deeper on lactobacillus rhamnosus TT-628.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus TT-628.

Explore the full profile